Johnson & Johnson approaches Actelion about takeover deal

A general view shows Swiss biotech group Actelion Headquarters in AllschwilBy Paul Arnold and Ludwig Burger ZURICH/FRANKFURT (Reuters) – U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe&;s largest biotech firm, currently valued at about $20 billion. Lung disease specialist Actelion confirmed it had been approached and said there was no certainty a deal would occur. An acquisition of the Swiss company would boosts J&J&039;s drug pipeline and diversify its prospects.

Go to Source

Actelion shares surge on reported J&J takeover approach

A general view shows Swiss biotech group Actelion Headquarters in AllschwilBy Paul Arnold and Ludwig Burger ZURICH/FRANKFURT (Reuters) – Shares in Actelion Ltd jumped as much as 19 percent to record highs on Friday on reports that U.S. healthcare company Johnson & Johnson was interested in a takeover of the fast-growing Swiss biotechnology firm. A person familiar with the situation told Reuters that Johnson & Johnson (J&J) had met Actelion about a deal, and that there was broader interest from prospective suitors in the industry, after Bloomberg on Thursday reported J&J&;s interest.Deliberations were still at an early stage and Actelion was working with an adviser to explore options, Bloomberg said in its report.

Go to Source

West Africa tackles human and animal health together to contain diseases

By Kieran Guilbert DAKAR (Thomson Reuters Foundation) – A drive by West African nations to tackle zoonotic diseases, those that jump from animals to humans, could help to protect the region from future health crises such as the world’s worst Ebola outbreak, a United Nations official said on Thursday. Ministers from the region met in Senegal last week to adopt an approach to infectious diseases that will address human and animal health together, and see countries work collaboratively to contain outbreaks of diseases ranging from bird flu to Zika. Three-quarters of emerging infectious diseases in recent years have spread to humans from animals or animal products, according to the World Health Organization (WHO).
Go to Source

Lilly drug for Alzheimer’s fails in big study; shares drop

Eli Lilly and Co said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of people at risk of developing the memory-robbing disease. Lilly shares were down nearly 16 percent in premarket trading after the U.S. drugmaker unveiled the long-awaited results of its large Expedition 3 study. Shares of Biogen Inc, which is developing a similar drug, fell more than 8 percent.
Go to Source

European parliament passes watered-down draft law on air pollution

The European Parliament passed a new draft law on air pollution on Wednesday that the European Commission and several members of parliament (MEPs) said was not enough to cut emissions to World Health Organization standards. The law, which has taken almost three years to get through parliament, aims to halve the number of premature deaths caused by air pollution from more than 400,000, and targets the many EU states already in breach of existing air pollution limits. A European Environment Agency (EEA) report published on Wednesday showed that member states across the bloc far exceed annual limits for nitrogen dioxide (NO2) emissions and at least 10 states breached limits on other pollutants in 2014.
Go to Source

1 2 3 4 9